

**Draft agenda**  
**35<sup>th</sup> meeting of the Biocidal Products Committee (BPC)**

**16 - 18 June 2020**

**Meeting is held virtually via WebEx**

**Starts on 16 June at 10:30,  
ends on 18 June at 14:00**

**The time is indicated in Helsinki time.**

**1. – Welcome and apologies**

**2. – Agreement of the agenda**

BPC-A-35-2020  
*For agreement*

**3. – Declarations of potential conflicts of interest to agenda items**

**4. – Agreement of the minutes and review of actions from BPC-34**

BPC-M-34-2020  
*For agreement*

**5. – Administrative issues**

**5.1. Administrative issues**

*For information*

**6. – Work programme for BPC**

**6.1. BPC Work Programmes for active substance approval, Union  
authorisation, ED assessment and outlook for BPC**

BPC-35-2020-01; BPC-35-2020-02; BPC-35-2020-03; BPC-35-2020-04

*For information*

## 7. – Applications for approval of active substances\*

### 7.1. Draft BPC opinion on carbon dioxide generated from propane, butane or a mixture of both by combustion for PT 19

*Previous discussion: WG-I-2020*

BPC-35-2020-05A, B, C

***For adoption***

### 7.2. Draft BPC opinion on C(M)IT for PT 6

*Previous discussion: WG-I-2020*

BPC-35-2020-06A, B, C

***For adoption***

### 7.3. Draft BPC opinions on active chlorine generated from sodium chloride by electrolysis for PT 1, 2, 3, 4 and 5

*Previous discussions: BPC-25; WG-I-2020*

**PT 1:** BPC-35-2020-07A, B, C

**PT 2:** BPC-35-2020-08A, B, C

**PT 3:** BPC-35-2020-09A, B, C

**PT 4:** BPC-35-2020-10A, B, C

**PT 5:** BPC-35-2020-11A, B, C

***For adoption***

### 7.4. Draft BPC opinions on active chlorine released from hypochlorous acid for PT 1, 2, 3, 4 and 5

*Previous discussions: BPC-25; WG-I-2020*

**PT 1:** BPC-35-2020-12A, B, C

**PT 2:** BPC-35-2020-13A, B, C

**PT 3:** BPC-35-2020-14A, B, C

**PT 4:** BPC-35-2020-15A, B, C

**PT 5:** BPC-35-2020-16A, B, C

***For adoption***

### 7.5. Draft BPC opinion on esbiothrin for PT 18

*Previous discussions: WG-III-2017, WG-V-2018*

BPC-35-2020-17A, B, C

***For adoption***

---

\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

## 8. – Union authorisation\*\*

- 8.1 Listing of precautionary statements in section 3 and 5.3 of the SPC**  
BPC-35-2020-18  
***For agreement***
- 8.2 Draft BPC opinion on Union authorisation applications for a product family containing propan-2-ol**  
*Previous discussion: WG-I-2020*  
BPC-35-2020-19A, B, C, D  
***For adoption***
- 8.3 Draft BPC opinion on Union authorisation applications for a product family containing 1R-trans phenothrin**  
*Previous discussion: WG-I-2020*  
BPC-35-2020-20A, B, C, D  
***For adoption***
- 8.4 Draft BPC opinion on Union authorisation applications for a product family containing permethrin**  
*Previous discussion: WG-I-2020*  
BPC-35-2020-21A, B, C, D  
***For adoption***
- 8.5 Draft BPC opinion on Union authorisation applications for a product family containing hydrogen peroxide**  
*Previous discussions: WG-II-2019; WG-V-2019; WG-I-2020*  
BPC-35-2020-22A, B, C, D  
***For adoption***

## 9. - Any other business

- 9.1 Harmonised List of Endpoints for pyrethroid metabolites – environmental hazards**  
BPC-35-2020-23  
***For agreement***
- 9.2 Revision ECHA Guidance Volume III Human Health Information Requirements**  
BPC-35-2020-24  
***For information***

---

\*\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by D).

**9.3 Sensitisers and quantitative risk assessment (QRA)**

BPC-35-2020-25

*For discussion*

**10. - Action points and conclusions**

*Via written procedure*

**Provisional time schedule for the  
35<sup>th</sup> meeting of the Biocidal Products Committee (BPC)  
Virtual meeting via WebEx  
16 June 2020: starts at 10:30; 18 June 2020 ends at 14:00**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

**Tuesday 16 June: morning session (starts at 10:30)**

Items 1-5	Opening items and administrative issues
Item 6.1	BPC Work Programme for active substance approval, BPC Work Programme for Union authorisation, Outlook for BPC, Status ED assessment for active substances
Item 7.1	Draft BPC opinion on carbon dioxide generated from propane, butane or a mixture of both by combustion for PT 19
Item 7.2	Draft BPC opinion on C(M)IT for PT 6

**Tuesday 16 June: afternoon session**

Item 7.2	(cont'd)
Item 7.3	Draft BPC opinions on active chlorine generated from sodium chloride by electrolysis for PT 1, 2, 3, 4 and 5
Item 7.4	Draft BPC opinions on active chlorine released from hypochlorous acid for PT 1, 2, 3, 4 and 5
Item 7.5	Draft BPC opinion on esbiothrin for PT 18

**Wednesday 17 June: morning session (starts at 10:30)**

Item 8.1	Listing of precautionary statements in section 3 and 5.3 of the SPC
Item 8.2	Draft BPC opinion on Union authorisation applications for a product family containing propan-2-ol
Item 8.3	Draft BPC opinion on Union authorisation applications for a product family containing 1R-trans phenothrin

**Wednesday 17 June: afternoon session**

Item 8.3	(cont'd)
Item 8.4	Draft BPC opinion on Union authorisation applications for a product family containing permethrin

**Thursday 18 June: morning session (starts at 10:30)**

- Item 8.5 Draft BPC opinion on Union authorisation applications for a product family containing hydrogen peroxide
- Item 9.1 Harmonised List of Endpoints for pyrethroid metabolites – environmental hazards
- Item 9.2 Revision ECHA Guidance Volume III Human Health Information Requirements
- Item 9.3 Sensitisers and quantitative risk assessment (QRA)
- Item 10 Action points and conclusions

End of meeting

oOo